Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 31NET 29CNS 10Gastrointestinal 8Genitourinary 2Dermatologic 2Thoracic 1Sarcoma 1Other neoplasm 1Breast 1

Conditions

Digestive System Neuroendocrine Tumor G1 1

Interventions

fludarabine 5Educational Status 5fludarabine phosphate 4Whole-Body Irradiation 4Mycophenolic Acid 4Methods 4Melphalan 4Magnetic Resonance Spectroscopy 4Early Intervention, Educational 4Cyclophosphamide 4Busulfan 4Biopsy 4Taxes 3Tacrolimus 3Specimen Handling 3Peripheral Blood Stem Cell Transplantation 3Paclitaxel 3Interviews as Topic 3venetoclax 2Sirolimus 2Patient Reported Outcome Measures 2Nivolumab 2Mesna 2Health Promotion 2Colposcopy 2Cisplatin 2Aminolevulinic Acid 2Albumin-Bound Paclitaxel 2toripalimab 1tirbanibulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
lutetium Lu 177 dotatate × Other neoplasm × 1 year × Clear all
NCT06016855 2025-12-17

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Vanderbilt-Ingram Cancer Center

Phase 4 Recruiting
6 enrolled
EndocrineGastrointestinalNETOther neoplasm

Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡